Akebia Therapeutics (NASDAQ:AKBA) Downgraded by StockNews.com to Sell
Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) was downgraded by research analysts at StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Monday. Separately, HC Wainwright reissued a “buy” rating and issued a $7.50 target price on shares of Akebia Therapeutics in a research report on Wednesday, October […]
More Stories
DOGE to Take on Pentagon’s $895.2 Billion Budget
By Jacob Burg Out of all the ambitions of President-elect Donald Trump’s upcoming Department of Government Efficiency (DOGE), one that...
Rio Tinto Group (RIO) – Analysts’ Weekly Ratings Changes
Several brokerages have updated their recommendations and price targets on shares of Rio Tinto Group (LON: RIO) in the last...
Sienna Resources (CVE:SIE) Trading Up 16.7% – What’s Next?
Shares of Sienna Resources Inc. (CVE:SIE – Get Free Report) shot up 16.7% on Wednesday . The stock traded as...
WisdomTree Emerging Markets Quality Dividend Growth Fund to Issue Dividend of $0.04 (NASDAQ:DGRE)
WisdomTree Emerging Markets Quality Dividend Growth Fund (NASDAQ:DGRE – Get Free Report) announced a dividend on Tuesday, December 24th,NASDAQ Dividends...
VictoryShares Free Cash Flow Growth ETF (NASDAQ:GFLW) Plans Dividend Increase – $0.00 Per Share
VictoryShares Free Cash Flow Growth ETF (NASDAQ:GFLW – Get Free Report) declared a dividend on Tuesday, December 24th,NASDAQ Dividends reports....
HHS Ends Push for Expanded Contraception Access, Keeps Trump-Era Employer Opt-Outs
By Tom Ozimek The Department of Health and Human Services (HHS) has withdrawn a set of proposed regulations aimed at...